Sunday, 13 September 2026 · Weekend Edition · 10:00 London

Oracle's founder just killed a $7.5bn sale. That's a signal.

Join Tom, Gerald and Marie for this edition's podcast · 9 min Spotify YouTube

Signals

⚡ Convergence radar: Buy ORCL×3

Oracle

Larry Ellison scrapped a plan to sell up to 50 million Oracle shares worth $7.5bn, one day after a filing revealed the programme, and confirmed no stock changed hands. FT, The Information and WSJ all carried the reversal, which removes a supply overhang and reads as founder confidence. ORCL sits 54% below its 52-week high and trades at 13.7x forward earnings, so the cancellation is doing more for narrative than the tape until cloud growth proves itself.

ORCL

Buy Oracle⚡ — Three sources confirm the $7.5bn sale cancellation with zero shares sold; ORCL is 54% below its 52-week high at 13.7x forward earnings, so founder confidence removes a supply overhang before any fundamental turn.

$150.3 -1.74%

Pharma rotation

WSJ Markets argues heart disease, the world's biggest killer, has become one of the hardest places for drugmakers and investors to profit, with cardiovascular pricing and generic competition eroding economics. That flips the standard 'large market equals large opportunity' logic and points capital toward companies that reach the same patients through better-priced products. Lilly and Novo's GLP-1 franchises capture the heart-disease pool without needing a cardiovascular label, while Pfizer leans on exactly the franchises under pressure. NVO is 33% below its 52-week high versus LLY 14% below, so the rotation has differentiation.

LLY

Buy Eli Lilly — Lilly's GLP-1 franchise captures heart-disease patients at far better economics, and LLY is 14% below its 52-week high, leaving room if the WSJ thesis accelerates rotation.

$1116 -0.65%
NVO

Buy Novo Nordisk — Same GLP-1 logic as Lilly; NVO is 33% below its 52-week high and -17.8% YTD, so the rotation case is less priced than Lilly's.

$43.07 -2.14%
PFE

Sell Pfizer — WSJ's single-source thesis flags Pfizer as most exposed to cardiovascular pricing pressure, and PFE is only 5% below its 52-week high after +10.1% YTD, a squeezed setup for the bear case.

$27.72 +0.25%

AI proxies

Sam Altman told Fortune an OpenAI IPO won't happen this year, calling safety concerns 'an ill-advised moment to go public'. CoinDesk and MarketWatch both carried the interview, which keeps OpenAI's equity story inside Microsoft and defers any separate market repricing. For listed AI rivals it removes a near-term capital-markets overhang; Google and Amazon keep cheaper funding than a private OpenAI stuck out of public markets. MSFT is 11% below its 52-week high, GOOGL 17%, AMZN 11%, so none have run away ahead of this.

MSFT

Buy Microsoft — CoinDesk and MarketWatch both flag the IPO delay; Microsoft's OpenAI stake keeps a private-gear optionality and MSFT trades 11% below its 52-week high.

$495.6 +0.65%
GOOGL

Buy Alphabet — Listed AI labs keep cheaper funding than private OpenAI, and GOOGL is 17% below its 52-week high at 22.8x forward earnings.

$338.5 +1.77%
AMZN

Buy Amazon — Amazon's listed-parent funding advantage holds while OpenAI stays private; AMZN sits 11% below its 52-week high after +13.4% YTD.

$256.8 +1.94%

India IPO

The Reserve Bank of India rejected Tata Sons' application to surrender its shadow-lender status, forcing the holding company toward rules that include a public listing. FT and Bloomberg both flag the coming deal as a candidate for India's biggest ever IPO, though no timetable or valuation is disclosed. A record-size listing would deepen the market and draw global flows, but it also raises questions about how the market reprices the group's listed subsidiaries, starting with TCS. INDA is -11.0% YTD and 13% below its 52-week high, so the catalyst arrives into a beaten-down tape.

INDA

Buy India equities — FT and Bloomberg both flag the record IPO; INDA trades 13% below its 52-week high and -11.0% YTD, so the catalyst offers re-rating optionality at a cheap entry.

$48.57 +0.96%
TCS.NS

Watch Tata Consultancy — A Tata Sons listing changes the holding-company discount on TCS; TCS.NS is 34% below its 52-week high, but the direction depends on future stake sales.

$2201 -0.15%

Japan steel

Nippon Steel spent 300 billion yen, or $1.96bn, on a new hot rolling line, its largest single-asset investment ever, with the line online in September 2026. Nikkei Asia frames it as a contrarian bet on taking automotive share from rivals even as domestic demand shrinks. The strategy funds capacity to attack JFE and smaller producers, while the U.S. Steel debt hangs on the balance sheet. We have no live quotes for the Japanese tickers, but the logic is clean: share-gain capex in a flat market is a zero-sum game.

5401.T

Buy Nippon Steel — Nikkei Asia's single-source story frames the $1.96bn line as share-gaining capacity for Nippon Steel, a volume and pricing tail if autos hold up.

5411.T

Sell JFE Holdings — Nippon Steel explicitly aims to take share from rivals, and JFE is the closest domestic competitor to lose volume.

SLX

Watch Steel ETF — New Asian auto-steel capacity adds to global glut, keeping sector pricing under pressure; SLX is 4% below its 52-week high after +26.1% YTD.

$109.0 +0.32%

Defence build-out

FT Companies reports German military start-up ARX Robotics wants carmakers' help to meet soaring demand for unmanned military vehicles, a carmaker-to-defence conversion angle. Separately, Nikkei Asia says Tokyo plans subsidies that support capital spending to build emergency capacity for ammunition and drones, naming Mitsubishi Heavy and NEC as drone partners and Fujitsu with General Atomics on UAV maintenance. Both stories broaden rearmament beyond the prime contractors and into industrial supply chains. RHM.DE is 51% below its 52-week high despite the theme, while VOW.DE trades at 0.23x book with defence revenue still small next to autos.

RHM.DE

Buy Rheinmetall — FT's ARX story plus Nikkei's Japan subsidy plan both point to broad rearmament demand, and RHM.DE is 51% below its 52-week high, the theme isn't priced.

€990.6 -2.54%
ITA

Buy US aerospace & defence — Both the European unmanned-vehicle push and Japan's subsidy plan lift the global defence sector; ITA is only -1.4% YTD and 15% below its high.

$219.0 +0.32%
7011.T

Buy Mitsubishi Heavy — Nikkei Asia names Mitsubishi Heavy as Japan's largest defence prime already building drones, so subsidised capex flows to it first.

VOW.DE

Watch Volkswagen — Carmaker-to-defence conversion could open new revenue, but VOW.DE at 0.23x book shows the market thinks auto problems dominate.

€81.20 -0.12%

Data centres

FT exclusive: campaigners want approval for Equinix's South African hyperscale data centre overturned, citing power and water supply as AI build-out strains local resources. That frames resource constraints as a real gate on data-centre growth in emerging markets, not just a Western NIMBY story. EQIX trades at 55.5x forward earnings, +35.8% YTD and only 8% below its 52-week high, it is pricing perfect permitting. A single precedent that delays projects in water-stressed markets is enough to rerate the sector's most expensive names.

EQIX

Sell Equinix — FT's single-source permitting challenge exposes utility-resource risk; EQIX at 55.5x forward earnings and 8% below its 52-week high prices perfect execution.

$1038 +1.36%
DLR

Watch Digital Realty — Same sector resource risk, but DLR is 9% below its 52-week high and 65.2x forward earnings; watch whether the South Africa case spreads to other hyperscale sites.

$188.6 +1.73%

Vietnam

Nikkei Asia reports Vietnam's richest man Pham Nhat Vuong is transferring control of his business empire to his sons, opening a succession question across Vingroup listed arms including VIC, Vinhomes and Nasdaq-listed VinFast. For VinFast, the handover puts attention on its cash burn and reliance on Vuong's personal backing; for Vingroup, it's a strategic-direction wait-and-see. VIC.VN is +43.5% YTD and 8% below its 52-week high, VHM.VN +16.1% YTD, while VFS remains 39% below its high.

VIC.VN

Watch Vingroup — Succession at the parent is a governance wait-and-see for the listed conglomerate; VIC.VN is +43.5% YTD and 8% below its 52-week high.

$243300 -1.78%
VFS

Watch VinFast — Handover raises backing questions for the money-losing EV arm; VFS trades 39% below its 52-week high after -5.0% YTD.

$3.21 +6.64%
VHM.VN

Watch Vinhomes — The property arm is the group's cash engine; any strategic change matters most here, with VHM.VN +16.1% YTD and 17% below its high.

$72000 -1.50%

Recordati buyout

FT reports investors are accusing CVC of pressuring them to sell Recordati at a lowball €10.7bn take-private price, the kind of minority-shareholder revolt that historically forces a sweeter bid or invites a competing offer. The public fight cuts both ways: it raises REC.MI's odds of a higher cheque while damaging CVC's reputation with future sellers. REC.MI trades 5% below its 52-week high at 13.8x forward earnings, so a sweetened offer is not yet priced.

REC.MI

Buy Recordati — FT's single-source revolt over a lowball €10.7bn offer raises odds of a sweetened bid; REC.MI is only 5% below its 52-week high.

€52.00 +0.00%
CVC.AS

Sell CVC Capital — A public price fight risks a higher cheque and reputational damage; CVC.AS trades 16% below its 52-week high at 14.9x forward earnings.

€13.66 +0.07%

Thailand risk

Nikkei Asia reports Japan's Nidec will exit production in Cambodia because of the Thailand border conflict, a tangible supply-chain casualty from a regional flare-up most markets are ignoring. If manufacturers start pulling capacity out of the region, Thai investment and trade flows take the hit. THD is +23.7% YTD and sits just 1% below its 52-week high, which looks like the market hasn't priced any of this.

THD

Sell Thailand equities — A border conflict driving Nidec out of Cambodia hits Thai investment flows; THD is +23.7% YTD and within 1% of its 52-week high, leaving no discount for the risk.

$74.11 -0.08%
6594.T

Sell Nidec — Nidec's forced Cambodia exit adds relocation cost and disruption; no yfinance snapshot, but the single-source story is a clear negative.

Most original take

David Wainer · WSJ Markets · 12 Sept 2026

Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness

The WSJ argues the world's largest disease market has become pharma's worst business. Pricing pressure, generic displacement and a shift in R&D economics mean cardiovascular, historically a blockbuster drug category, now repels capital even as it remains the leading cause of death. The real money is in diseases where drugs can command premium pricing, like GLP-1 obesity and diabetes, which capture the cardiovascular patient pool without a cardiovascular label.

Read original ↗

Our view

Today's signals point to two quiet forces: founders and regulators moving faster than markets. Ellison cancels a $7.5bn Oracle sale one day after filing, and ORCL sits 54% below its 52-week high at 13.7x forward earnings. Meanwhile the RBI forces Tata Sons toward India's biggest IPO, and Tokyo subsidises emergency drone and ammunition capacity. The common thread is capital being pulled or redirected, not left to markets.

The case against reading founder signals as alpha: ORCL is down 23.2% YTD for a reason, and one cancelled sale doesn't fix cloud competition. The defence build-out thesis has been around for years, RHM.DE is still 51% below its high despite the rearmament narrative, telling you either the easy money is gone or the market doesn't believe the backlog converts. If carmakers treat defence work as marginal, VOW.DE at 0.23x book becomes a value trap, not a re-rating story.

What we'd expect but don't see: any coverage of how a forced Tata Sons listing prices the holding-company discount across the entire Tata complex. FT and Bloomberg both flag the IPO but no one does the arb, TCS.NS trades 34% below its 52-week high and a Tata Sons listing is the cleanest vehicle to reprice that. That silence is the trade.

The cleanest cross-market expression isn't a single ticker. It's the spread between resource-rich data-centre owners and resource-constrained build-outs, EQIX at 55.5x forward earnings and +35.8% YTD is pricing perfect permitting; the South Africa challenge says that's not guaranteed. We'd fade the most-priced-in leg of the AI infrastructure trade, not the whole sector.

Yesterday's signals, today

From the Weekend Edition on 12 Sept 2026 — 0/2 signals moved in the predicted direction.

Today's scan: 92 articles considered · 15 surfaced · across 12 publishers

Generated Sun 13 Sept 2026 9:05am London · 30,072 views

Bloomberg Markets · CNBC Investing · CNBC Markets · CoinDesk · FT Alphaville · FT Companies · FT Lex · FT Markets · MarketWatch Top · Nikkei Asia · SCMP Business · The Information · WSJ Business · WSJ Markets

Next edition: London Edition tomorrow at 07:30 London.

Methodology
Share this edition